XKH001 clinical trials
Also written XKH001.
How each study uses XKH001 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the XKH001 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
6 studies that test it; most in 2023 (3)
| Year | Studies |
|---|---|
| 2023 | 3 |
| 2025 | 1 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 6 · Other 0
Zhejiang Kanova Biopharmaceutical Co., LTD (4) · Beijing Kanova Biopharmaceutical Co., LTD (2)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test XKH001.
- Apr 2027Bridging Study of XKH001 in Healthy Adult Caucasian ParticipantsPhase 1 · Zhejiang Kanova Biopharmaceutical Co., LTD
Studies
Open first, then newest update. How each study uses XKH001 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 6
- Bridging Study of XKH001 in Healthy Adult Caucasian ParticipantsNot yet recruitingPhase 1Zhejiang Kanova Biopharmaceutical Co., LTDNCT07757659Written as XKH001 Injection
- Phase II Clinical Study to Evaluate the Efficacy and Safety of XKH001 InjectionNot yet recruitingPhase 2Zhejiang Kanova Biopharmaceutical Co., LTDNCT07519499Written as XKH001Injection
- Evaluate the Efficacy and Safety of XKH001 Injection in Patients With Moderate-to-Severe Atopic DermatitisNot yet recruitingPhase 2Zhejiang Kanova Biopharmaceutical Co., LTDNCT07054736Written as XKH001 Injection
- XKH001 Injection in Healthy SubjectsCompletedPhase 1/2Beijing Kanova Biopharmaceutical Co., LTDNCT05991661Written as XKH001 Injection
- A Single-Arm Phase Ic Clinical Study of XKH001 Injection in Patients With Allergic Asthma After Multiple DosesCompletedPhase 1Zhejiang Kanova Biopharmaceutical Co., LTDNCT07070297Written as XKH001 Injection
- Phase I of XKH001Injection in Healthy AdultsStatus unknownPhase 1Beijing Kanova Biopharmaceutical Co., LTDNCT05128409Written as XKH001 Injection